These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
355 related articles for article (PubMed ID: 30174307)
1. Increased Lactate Secretion by Cancer Cells Sustains Non-cell-autonomous Adaptive Resistance to MET and EGFR Targeted Therapies. Apicella M; Giannoni E; Fiore S; Ferrari KJ; Fernández-Pérez D; Isella C; Granchi C; Minutolo F; Sottile A; Comoglio PM; Medico E; Pietrantonio F; Volante M; Pasini D; Chiarugi P; Giordano S; Corso S Cell Metab; 2018 Dec; 28(6):848-865.e6. PubMed ID: 30174307 [TBL] [Abstract][Full Text] [Related]
2. Fibroblast-secreted hepatocyte growth factor mediates epidermal growth factor receptor tyrosine kinase inhibitor resistance in triple-negative breast cancers through paracrine activation of Met. Mueller KL; Madden JM; Zoratti GL; Kuperwasser C; List K; Boerner JL Breast Cancer Res; 2012 Jul; 14(4):R104. PubMed ID: 22788954 [TBL] [Abstract][Full Text] [Related]
3. Cancer-associated fibroblasts promote epithelial-mesenchymal transition and EGFR-TKI resistance of non-small cell lung cancers via HGF/IGF-1/ANXA2 signaling. Yi Y; Zeng S; Wang Z; Wu M; Ma Y; Ye X; Zhang B; Liu H Biochim Biophys Acta Mol Basis Dis; 2018 Mar; 1864(3):793-803. PubMed ID: 29253515 [TBL] [Abstract][Full Text] [Related]
4. Norcantharidin combined with EGFR-TKIs overcomes HGF-induced resistance to EGFR-TKIs in EGFR mutant lung cancer cells via inhibition of Met/PI3k/Akt pathway. Wu H; Fan F; Liu Z; Shen C; Wang A; Lu Y Cancer Chemother Pharmacol; 2015 Aug; 76(2):307-15. PubMed ID: 26063323 [TBL] [Abstract][Full Text] [Related]
5. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells. Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343 [TBL] [Abstract][Full Text] [Related]
6. Dual inhibition of Met kinase and angiogenesis to overcome HGF-induced EGFR-TKI resistance in EGFR mutant lung cancer. Takeuchi S; Wang W; Li Q; Yamada T; Kita K; Donev IS; Nakamura T; Matsumoto K; Shimizu E; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S Am J Pathol; 2012 Sep; 181(3):1034-43. PubMed ID: 22789825 [TBL] [Abstract][Full Text] [Related]
7. Secretion of high amounts of hepatocyte growth factor is a characteristic feature of cancer-associated fibroblasts with EGFR-TKI resistance-promoting phenotype: A study of 18 cases of cancer-associated fibroblasts. Suzuki E; Yamazaki S; Naito T; Hashimoto H; Okubo S; Udagawa H; Goto K; Tsuboi M; Ochiai A; Ishii G Pathol Int; 2019 Aug; 69(8):472-480. PubMed ID: 31339210 [TBL] [Abstract][Full Text] [Related]
8. Hepatocyte growth factor reduces susceptibility to an irreversible epidermal growth factor receptor inhibitor in EGFR-T790M mutant lung cancer. Yamada T; Matsumoto K; Wang W; Li Q; Nishioka Y; Sekido Y; Sone S; Yano S Clin Cancer Res; 2010 Jan; 16(1):174-83. PubMed ID: 20008840 [TBL] [Abstract][Full Text] [Related]
9. [Tumor microenvironment elicits primary resistance to afatinib through HGF secretion]. Kang XH; Wang LF; Cao F; Fan FT; Xu ZY Zhonghua Zhong Liu Za Zhi; 2013 Oct; 35(10):732-6. PubMed ID: 24378092 [TBL] [Abstract][Full Text] [Related]
10. MicroRNA-34a overcomes HGF-mediated gefitinib resistance in EGFR mutant lung cancer cells partly by targeting MET. Zhou JY; Chen X; Zhao J; Bao Z; Chen X; Zhang P; Liu ZF; Zhou JY Cancer Lett; 2014 Sep; 351(2):265-71. PubMed ID: 24983493 [TBL] [Abstract][Full Text] [Related]
11. Resistance to targeted cancer drugs through hepatocyte growth factor signaling. Heynen GJ; Fonfara A; Bernards R Cell Cycle; 2014; 13(24):3808-17. PubMed ID: 25426675 [TBL] [Abstract][Full Text] [Related]
12. Transient PI3K inhibition induces apoptosis and overcomes HGF-mediated resistance to EGFR-TKIs in EGFR mutant lung cancer. Donev IS; Wang W; Yamada T; Li Q; Takeuchi S; Matsumoto K; Yamori T; Nishioka Y; Sone S; Yano S Clin Cancer Res; 2011 Apr; 17(8):2260-9. PubMed ID: 21220474 [TBL] [Abstract][Full Text] [Related]
13. CAF-derived HGF promotes cell proliferation and drug resistance by up-regulating the c-Met/PI3K/Akt and GRP78 signalling in ovarian cancer cells. Deying W; Feng G; Shumei L; Hui Z; Ming L; Hongqing W Biosci Rep; 2017 Apr; 37(2):. PubMed ID: 28258248 [TBL] [Abstract][Full Text] [Related]
14. Met kinase inhibitor E7050 reverses three different mechanisms of hepatocyte growth factor-induced tyrosine kinase inhibitor resistance in EGFR mutant lung cancer. Wang W; Li Q; Takeuchi S; Yamada T; Koizumi H; Nakamura T; Matsumoto K; Mukaida N; Nishioka Y; Sone S; Nakagawa T; Uenaka T; Yano S Clin Cancer Res; 2012 Mar; 18(6):1663-71. PubMed ID: 22317763 [TBL] [Abstract][Full Text] [Related]
16. Targeting the MET gene for the treatment of non-small-cell lung cancer. Gelsomino F; Facchinetti F; Haspinger ER; Garassino MC; Trusolino L; De Braud F; Tiseo M Crit Rev Oncol Hematol; 2014 Feb; 89(2):284-99. PubMed ID: 24355409 [TBL] [Abstract][Full Text] [Related]
17. Leukocyte Cell-Derived Chemotaxin 2 Retards Non-Small Cell Lung Cancer Progression Through Antagonizing MET and EGFR Activities. Hung WY; Chang JH; Cheng Y; Chen CK; Chen JQ; Hua KT; Cheng CW; Hsiao M; Chung CL; Lee WJ; Chien MH Cell Physiol Biochem; 2018; 51(1):337-355. PubMed ID: 30453282 [TBL] [Abstract][Full Text] [Related]
18. Podoplanin-positive cancer-associated fibroblasts in the tumor microenvironment induce primary resistance to EGFR-TKIs in lung adenocarcinoma with EGFR mutation. Yoshida T; Ishii G; Goto K; Neri S; Hashimoto H; Yoh K; Niho S; Umemura S; Matsumoto S; Ohmatsu H; Iida S; Niimi A; Nagai K; Ohe Y; Ochiai A Clin Cancer Res; 2015 Feb; 21(3):642-51. PubMed ID: 25388165 [TBL] [Abstract][Full Text] [Related]
19. The role of MET activation in determining the sensitivity to epidermal growth factor receptor tyrosine kinase inhibitors. Rho JK; Choi YJ; Lee JK; Ryoo BY; Na II; Yang SH; Lee SS; Kim CH; Yoo YD; Lee JC Mol Cancer Res; 2009 Oct; 7(10):1736-43. PubMed ID: 19808904 [TBL] [Abstract][Full Text] [Related]
20. Hepatocyte growth factor induces resistance to anti-epidermal growth factor receptor antibody in lung cancer. Yamada T; Takeuchi S; Kita K; Bando H; Nakamura T; Matsumoto K; Yano S J Thorac Oncol; 2012 Feb; 7(2):272-80. PubMed ID: 22089117 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]